About Xilio Therapeutics
Xilio Therapeutics is a company based in Waltham (United States) founded in 2016.. Xilio Therapeutics has raised $233 million across 5 funding rounds from investors including AbbVie, Takeda Pharmaceuticals and Ipsen. The company has 64 employees as of December 31, 2024. Xilio Therapeutics offers products and services including Vilastobart, XTX301, and XTX501. Xilio Therapeutics operates in a competitive market with competitors including Zymeworks, Harbour BioMed, Ambrx, Lassen Therapeutics and Leap Therapeutics, among others.
- Headquarter Waltham, United States
- Employees 64 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Xilio Therapeutics, Inc.
-
Annual Revenue
$6.34 M0as on Dec 31, 2024
-
Net Profit
$-58.24 M23.77as on Dec 31, 2024
-
EBITDA
$-58 M24.9as on Dec 31, 2024
-
Total Equity Funding
$233 M (USD)
in 5 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Feb 12, 2025
-
Investors
AbbVie
& 15 more
-
Employee Count
64
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Xilio Therapeutics
Xilio Therapeutics is a publicly listed company on the NASDAQ with ticker symbol XLO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Xilio Therapeutics
Xilio Therapeutics offers a comprehensive portfolio of products and services, including Vilastobart, XTX301, and XTX501. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets CTLA-4 for selective tumor immunotherapy in cancer treatment.
Delivers IL-12 to enhance immune response against tumors.
Focuses on masked T cell engagers for targeted cancer therapy.
Unlock access to complete
Unlock access to complete
Leadership Team
22 people
Scientific Team
9 people
Finance and Accounting
5 people
Human Resources and Administration
3 people
Product Management Team
3 people
Legal and Compliance
2 people
Scientist Team
2 people
Software Development Team
2 people
Unlock access to complete
Funding Insights of Xilio Therapeutics
Xilio Therapeutics has successfully raised a total of $233M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $10.0M
-
First Round
First Round
(12 Oct 2016)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Post-IPO - Xilio Therapeutics | Valuation |
investors |
|
| Jan, 2021 | Amount | Series C - Xilio Therapeutics | Valuation | Rock Springs Capital | |
| Mar, 2020 | Amount | Series B - Xilio Therapeutics | Valuation | Takeda Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Xilio Therapeutics
Xilio Therapeutics has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include AbbVie, Takeda Pharmaceuticals and Ipsen. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Xilio Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Xilio Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Xilio Therapeutics Comparisons
Competitors of Xilio Therapeutics
Xilio Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zymeworks, Harbour BioMed, Ambrx, Lassen Therapeutics and Leap Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Bi-specific antibodies and antibody-drug conjugates are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody therapeutics are developed for immunology and oncology diseases.
|
|
| domain | founded_year | HQ Location |
Antibody-drug conjugates are developed for cancers and metabolic disorders.
|
|
| domain | founded_year | HQ Location |
Biotherapeutics targeting cancer via interleukin-11 are developed.
|
|
| domain | founded_year | HQ Location |
Novel immuno-oncology therapeutics are acquired and developed for clinical advancement.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Xilio Therapeutics
Frequently Asked Questions about Xilio Therapeutics
When was Xilio Therapeutics founded?
Xilio Therapeutics was founded in 2016.
Where is Xilio Therapeutics located?
Xilio Therapeutics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Who is the current CEO of Xilio Therapeutics?
Rene Russo is the current CEO of Xilio Therapeutics.
Is Xilio Therapeutics a funded company?
Xilio Therapeutics is a funded company, having raised a total of $233M across 5 funding rounds to date. The company's 1st funding round was a Series B of $100.5M, raised on Oct 12, 2016.
How many employees does Xilio Therapeutics have?
As of Dec 31, 2024, the latest employee count at Xilio Therapeutics is 64.
What is the annual revenue of Xilio Therapeutics?
Annual revenue of Xilio Therapeutics is $6.34M as on Dec 31, 2024.
What does Xilio Therapeutics do?
Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, United States. Focus is placed on biotechnology, specifically the development of immunotherapies for cancer. Proprietary technology is utilized to engineer therapies activated selectively within tumors, minimizing systemic toxicity. Key candidates include XTX201, an IL-2 variant that promotes immune responses in tumors, along with XTX101, XTX301, and XTX401, which exhibit antitumor effects in preclinical studies.
Who are the top competitors of Xilio Therapeutics?
Xilio Therapeutics's top competitors include Ambrx, Harbour BioMed and BioAtla.
What products or services does Xilio Therapeutics offer?
Xilio Therapeutics offers Vilastobart, XTX301, and XTX501.
Is Xilio Therapeutics publicly traded?
Yes, Xilio Therapeutics is publicly traded on NASDAQ under the ticker symbol XLO.
Who are Xilio Therapeutics's investors?
Xilio Therapeutics has 16 investors. Key investors include AbbVie, Takeda Pharmaceuticals, Ipsen, RA Capital, and Atlas Venture.
What is Xilio Therapeutics's ticker symbol?
The ticker symbol of Xilio Therapeutics is XLO on NASDAQ.